B. Riley's Earnings Estimate for Viridian Therapeutics (VRDN) Q2 2025

On March 3rd, 2025, B. Riley analysts announced their estimated earnings for Viridian Therapeutics, Inc. (NASDAQ:VRDN) for the second quarter of 2025. Analyst K. Patel projects that the company will report an earnings loss of ($1.14) per share for this quarter. Currently, the overall consensus for Viridian's full-year earnings stands at ($4.03) per share.

Recently, Viridian Therapeutics released its latest quarterly earnings data on February 27th. The company showed an earnings per share (EPS) loss of ($0.81), which was better than the consensus estimate that predicted a loss of ($1.05) by $0.24. The reported revenue for the quarter was $0.07 million, exceeding the expected $0.05 million from analysts. Viridian faced a staggering net margin of -85,127.16% and had a negative return on equity of -70.12%.

Several analysts have shared insights into Viridian Therapeutics' stock performance. For instance, HC Wainwright maintained a “buy” rating and assigned a price target of $34.00 per share. Similarly, Needham & Company LLC reiterated a “buy” rating with a price target of $38.00. Royal Bank of Canada increased their price target for the stock from $44.00 to $47.00, also giving it an “outperform” rating. However, Wells Fargo & Company adjusted its rating to “equal weight” with a reduced price target of $27.00, down from $37.00. TD Cowen also started covering the stock with a “buy” recommendation. Overall, there are currently three analysts rating the stock as a hold and nine recommending it as a buy. MarketBeat.com shows the consensus rating on the company as “Moderate Buy” with an average price target of $35.70.

Viridian Therapeutics Stock Overview

As of Tuesday, shares of VRDN began trading at $15.23. Over the past year, the stock has seen a low of $11.40 and a high of $27.20. The company maintains a debt-to-equity ratio of 0.04, along with an impressive quick and current ratio of 18.55. The 50-day moving average price is $18.02, while the 200-day moving average stands at $19.70. Viridian Therapeutics has a market capitalization of $1.21 billion with a price-to-earnings ratio of -3.53 and a beta of 1.32.

Institutional Investment Activity

In recent times, significant institutional investors have made adjustments to their positions in VRDN. Great Point Partners LLC increased its shareholding by 50.0% during the third quarter, acquiring a total of 750,000 shares valued at $17,062,000 after an additional purchase of 250,000 shares. Lord Abbett & Company LLC took a new position in Viridian during the same quarter, worth $8,917,000. Notably, JPMorgan Chase & Co. increased its stake by 218.5%, adding 274,641 shares for a total of 400,351 shares valued at $9,108,000. Similarly, Barclays PLC raised its holdings by 113.1%, owning 125,397 shares valued at $2,851,000 after acquiring 66,550 shares. Point72 Asset Management L.P. also entered the third quarter with a new stake in the company valued at $788,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc. is a biotechnology firm dedicated to discovering and developing treatments for rare diseases. Its product pipeline includes VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, currently in Phase 3 trials for thyroid eye disease (TED), and VRDN-003, a next-generation IGF-1R humanized monoclonal antibody designed for TED treatment.

Earnings, Stocks, Analysis